Madrigal Pharmaceuticals 주식 (NASDAQ: MDGL)

에 대한 최신 뉴스 Madrigal Pharmaceuticals (NASDAQ:MDGL) 주식

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Mid Cap

News

Topics

Movers

Trading Ideas

AAPL

GSAT

MDGL

OMCL

PRCT

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 마드리갈 파마슈티컬스(NASDAQ:MDGL)의 주식은 회사가 예상보다 좋은 실적을 발표한 후 51.70% 상승했다.

글로벌스타와 넥스트래커는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 28일-11월 1일)

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

RBC Capital analyst Matthew McKellar reiterates Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Outperform and maintains $58 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Smurfit WestRock, Maintains $58 Price Target

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Biotech

Large Cap

Eurozone

Health Care

General

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

WIIM

NDRA

ENDRA Life Sciences shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Stephen Boland maintains CI Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIX#TSX">CIX</a>) with a Outperform and raises the price target from C$22 to C$27.

TSX:CIX

Raymond James Maintains Outperform on CI Financial, Raises Price Target to C$27

ALRN

Aileron Therapeutics shares are trading lower. The company reported Q3 financial results.

RBC Capital analyst Jimmy Shan maintains Flagship Communities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MHC#TSX">MHC</a>) with a Outperform and raises the price target from C$19 to C$20.

TSX:MHC

TSX:MHC/U

RBC Capital Maintains Outperform on Flagship Communities, Raises Price Target to C$20

OMGA

Omega Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results and Piper Sandler cut its price target on the stock from $9 to $4.

ALUR

Allurion Technologies shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.

BMO Capital analyst Ben Pham maintains Boralex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLX#TSX">BLX</a>) with a Outperform and lowers the price target from C$46 to C$45.

TSX:BLX

BMO Capital Maintains Outperform on Boralex, Lowers Price Target to C$45

VUZI

Vuzix shares are trading lower after the company reported worse-than-expected Q3 financial results.

Deep-pocketed investors have adopted a bearish approach towards Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TEM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Tempus AI. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 50% bearish. Among these notable options, 6 are puts, totaling $683,586, and 2 are calls, amounting to $99,000.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $55.0 for Tempus AI during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Tempus AI's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $30.0 to $55.0 in the last 30 days. 
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687434_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$4.5</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$246.2K</td>
<td align="right">85</td>
<td align="right">500</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.3</td>
<td>$5.0</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$225.7K</td>
<td align="right">85</td>
<td align="right">462</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.7</td>
<td>$4.3</td>
<td>$4.7</td>
<td>$52.00</td>
<td>$92.5K</td>
<td align="right">206</td>
<td align="right">200</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$9.2</td>
<td>$7.7</td>
<td>$9.2</td>
<td>$55.00</td>
<td>$63.4K</td>
<td align="right">10</td>
<td align="right">90</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$23.7</td>
<td>$22.0</td>
<td>$23.0</td>
<td>$30.00</td>
<td>$50.6K</td>
<td align="right">0</td>
<td align="right">44</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
After a thorough review of the options trading surrounding Tempus AI, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Tempus AI</h3>
<ul>
<li>With a trading volume of 572,433, the price of TEM is up by 0.32%, reaching $56.81.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $67.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $70. 
&#x2A; Reflecting concerns, an analyst from Stifel lowers its rating to Hold with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Behind the Scenes of Tempus AI's Latest Options Trends

Deep-pocketed investors have adopted a bearish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 19% leaning bullish and 71% bearish. Among these notable options, 11 are puts, totaling $1,047,442, and 10 are calls, amounting to $2,142,826.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $140.0 for Trade Desk during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trade Desk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trade Desk's significant trades, within a strike price range of $90.0 to $140.0, over the past month.
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687428_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$34.85</td>
<td>$34.25</td>
<td>$34.4</td>
<td>$90.00</td>
<td>$1.0M</td>
<td align="right">746</td>
<td align="right">301</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.5</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$105.00</td>
<td>$608.5K</td>
<td align="right">16</td>
<td align="right">644</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.2</td>
<td>$32.0</td>
<td>$32.0</td>
<td>$92.50</td>
<td>$320.0K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$32.8</td>
<td>$31.05</td>
<td>$32.4</td>
<td>$92.50</td>
<td>$181.4K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.2</td>
<td>$26.75</td>
<td>$27.09</td>
<td>$115.00</td>
<td>$162.8K</td>
<td align="right">486</td>
<td align="right">60</td>
</tr>
</tbody>
</table>

<h3>About Trade Desk</h3>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>With a volume of 1,511,116, the price of TTD is down -1.1% at $124.49. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Trade Desk</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $109.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Trade Desk with a target price of $135. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on Trade Desk, maintaining a target price of $134. 
&#x2A; An analyst from New Street Research has revised its rating downward to Sell, adjusting the price target to $86. 
&#x2A; An analyst from Benchmark downgraded its action to Sell with a price target of $57. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Trade Desk with a target price of $135. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Trade Desk

Investors with a lot of money to spend have taken a bearish stance on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Nike.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 52%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $888,906, and 9 are calls, for a total amount of $375,233.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $95.0 for Nike, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Nike's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Nike's significant trades, within a strike price range of $60.0 to $95.0, over the past month.
<h3>Nike Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687423_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.53</td>
<td>$2.53</td>
<td>$75.00</td>
<td>$126.5K</td>
<td>16.5K</td>
<td>526</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.53</td>
<td>$2.46</td>
<td>$2.51</td>
<td>$75.00</td>
<td>$125.2K</td>
<td>16.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.35</td>
<td>$95.00</td>
<td>$82.7K</td>
<td>1.8K</td>
<td>1</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.1</td>
<td>$80.00</td>
<td>$67.7K</td>
<td>12.0K</td>
<td>222</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.08</td>
<td>$80.00</td>
<td>$67.0K</td>
<td>12.0K</td>
<td>111</td>
</tr>
</tbody>
</table>

<h3>About Nike</h3>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
Following our analysis of the options activities associated with Nike, we pivot to a closer look at the company's own performance.
<h3>Where Is Nike Standing Right Now?</h3>
<ul>
<li>With a volume of 3,359,657, the price of NKE is up 0.86% at $76.33. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 34 days.</li>
</ul>
<h3>What Analysts Are Saying About Nike</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $80.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Nike with a target price of $80. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Nike, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Nike's Latest Options Trends

Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) stock has climbed following Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election win</a>, driven by expectations of economic policies that could stimulate consumer spending and benefit payment processors like Visa.
Trump's proposal to extend and expand tax cuts is likely to increase disposable income for households and encourage corporate investment, leading to a surge in transaction volumes—Visa's primary revenue source.
What Else: Additionally, Trump's deregulatory agenda could benefit Visa by reducing compliance costs in the financial sector, allowing the company to invest more aggressively in innovation. 
This could accelerate Visa's development of digital payment technologies, enhance its global network, and foster partnerships with emerging fintech companies. Visa is well-positioned to capitalize on this growth as digital transactions continue to replace cash worldwide.
Trump's focus on economic expansion through infrastructure spending and trade reforms could further bolster Visa's business segment by increasing corporate transactions and cross-border payment activity. 
Potential inflationary pressures under Trump's policies may also indirectly benefit Visa, as higher transaction values generate increased processing fees.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42006281/alibaba-q2-earnings-revenue-beats-forecast-cloud-and-international-sales-shine-free-cash-flow-falls-amid-strategic-investments">Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments</a>
<h2 class="wp-block-heading">Is V A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/V">Visa</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Visa does pay a dividend, which yields 0.78% per year as of the closing price on Nov. 15, 2024. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/V">Visa</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, V has a 52-week high of $312.44 and a 52-week low of $245.60.

Why Visa Stock Hit A New 52-Week High This Week

The Oncology Institute shares are trading lower. The stock may be moving on continued weakness following worse-than-expected Q3 financial results reported on Wednesday.

Nvidia CEO Jensen Huang and SoftBank&#8217;s Masayoshi Son recently shared a few laughs and some bittersweet memories at the AI Summit in Tokyo. At the center of their banter? SoftBank&#8217;s former role as Nvidia&#8217;s largest shareholder – and how they decided to let that golden opportunity slip away.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Billionaires Jensen Huang and Masayoshi Son joke about how SoftBank was once Nvidia&#39;s largest shareholder — before dumping its stake. The two are now joining forces on an AI supercomputer <a href="https://t.co/UjUIVaCinN">https://t.co/UjUIVaCinN</a> <a href="https://t.co/rfd1p1yKB0">pic.twitter.com/rfd1p1yKB0</a>
&mdash; Bloomberg (@business) <a href="https://twitter.com/business/status/1856563439331618846?ref_src=twsrc%5Etfw">November 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
In 2019, SoftBank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) sold all of its Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares, which comprised about 4.9% of the company. It seemed like a solid move back then: they had invested around $700 million and ended up making $3.3 billion from the sale. But now, Son admits the decision wasn&#8217;t exactly a home run. Today, <a href="https://www.benzinga.com/general/24/06/39489510/the-150-billion-opportunity-softbank-lost-by-selling-nvidia-shares-too-soon">those shares would be worth over $150 billion</a>.
During their talk, Huang jokingly said, &#8220;We can cry together,&#8221; hugging Son on stage as they remembered what might have been. Son, not missing a beat, added that he had to &#8220;tearfully&#8221; sell those shares. Huang even shared that Son once offered him financial backing to buy Nvidia outright – something he now wishes he'd taken. &#8220;That was a great idea,&#8221; Huang said, with a hint of regret.
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Huang praised Son for being a visionary who has consistently backed winning innovators like Bill Gates, Jerry Yang and Steve Jobs. Son has a talent for recognizing big opportunities and helping establish major tech moments, from bringing Gates and Jobs to Japan to making Alibaba&#8217;s success possible in China. Yet, even with all those successes, the missed Nvidia chance still stings.
Today, <a href="https://www.benzinga.com/quote/NVDA">Nvidia is worth $3.6 trillion</a> and is the world&#8217;s most valuable company, ahead of tech giants like Apple and Microsoft. Its value has skyrocketed thanks to the AI boom, with its chips playing a crucial role in powering AI technologies across the globe. Nvidia&#8217;s stock has surged 2,768% in the last five years, putting <a href="https://www.benzinga.com/startups/24/11/41882908/640416">Jensen Huang&#8217;s net worth</a> at a staggering $127 billion.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
SoftBank, meanwhile, remains heavily invested in the future of AI. Son has made it clear that he&#8217;s not done yet. He recently mentioned that his true purpose might be to <a href="https://www.benzinga.com/news/24/10/41181374/softbanks-masayoshi-son-predicts-artificial-superintelligence-within-a-decade-after-testing-openais">bring about artificial superintelligence (ASI) – </a>a form of AI that could be 10,000 times smarter than humans. His belief in the power of AI and its ability to solve global problems, from diseases to natural disasters, keeps driving him forward.
Despite the missed opportunity with Nvidia, SoftBank is moving ahead at full throttle. Son and Huang recently <a href="https://www.benzinga.com/news/global/24/11/41929194/nvidia-and-softbank-to-build-japans-top-ai-supercomputer-on-blackwell-platform-jensen-huang-says-tokyo-is-leaping-into-the-ai-industrial-revolution">announced a partnership</a> to build Japan&#8217;s most powerful AI supercomputer using Nvidia&#8217;s latest Blackwell chips. The goal? To establish Japan as a major player in AI, with applications that could transform industries like telecommunications, health care and transportation.
Read Next:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Startups

NVDA

SFTBF

Must See: Billionaires Jensen Huang And Masayoshi Son Joke About SoftBank's Past As Nvidia's Largest Shareholder – Before Dumping Its Stake

RBC Capital analyst Arthur Nagorny maintains Mattr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MATR#TSX">MATR</a>) with a Outperform and lowers the price target from C$20 to C$18.

TSX:MATR

RBC Capital Maintains Outperform on Mattr, Lowers Price Target to C$18

Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are trading lower on Friday. The company partnered with National Auto Fleet Group (NAFG) to sell its all-electric Class 4 Bollinger B4 commercial <a href="https://www.benzinga.com/pressreleases/24/11/g42008604/mullen-subsidiary-bollinger-motors-partners-with-national-auto-fleet-group-for-government-fleet-ve" target="_blank" rel="noreferrer noopener">trucks to government agencies</a>.
The Bollinger B4 Chassis Cab, a fully electric Class 4 commercial truck, offers a range of 185 miles and a payload capacity of 7,394 pounds.
The Bollinger B4 is ideal for commercial, government, and municipal fleets seeking a versatile, high-performance truck for a variety of tasks.
Bollinger CRO Jim Connelly said, &#8220;Government agencies and municipalities are often early adopters for electrification and electric vehicle fleets. We look forward to partnering with NAFG, and their history of bringing innovative products and solutions to this important segment.&#8221;
Mullen announced its Class 1 EV cargo van, the Mullen ONE, is available for rent on Turo, a vehicle-sharing marketplace. The effort is in collaboration with Parasol Strategic Solutions,<a href="https://www.benzinga.com/trading-ideas/movers/24/11/41913722/whats-going-on-with-mullen-automotive-stock-tuesday-2" target="_blank" rel="noreferrer noopener"> a high-level Turo host based in Florida</a>.
Last month, Bollinger Motors completed its first West Coast delivery of 2025 <a href="https://www.benzinga.com/markets/equities/24/10/41630662/mullens-bollinger-motors-marks-milestone-with-500-thousand-west-coast-ev-truck-delivery" target="_blank" rel="noreferrer noopener">Bollinger B4 trucks worth ~$500K</a>.
Also, Bollinger Motors completed its first customer delivery of the 2025&nbsp;Bollinger B4 Chassis Cab, generating $800,000 in revenue for the <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41166786/whats-going-on-with-mullen-automotive-stock-thursday" rel="noreferrer noopener">original equipment manufacturer</a>.
Price Action: Mullen Automotive shares are down 9.28% at $3.13, at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42011035" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Image: Courtesy of Mullen Automotive

Equities

Contracts

Small Cap

MULN

Mullen Drives Into Government Sector With Electric Bollinger B4 Trucks

BMO Capital analyst Stephen MacLeod reiterates CCL Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCL#TSX">CCL</a>) with a Outperform and raises the price target from C$90 to C$93.

TSX:CCL

TSX:CCL/B

BMO Capital Reiterates Outperform on CCL Industries, Raises Price Target to C$93

RBC Capital analyst Douglas Miehm maintains Medical Facilities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DR#TSX">DR</a>) with a Sector Perform and raises the price target from C$16 to C$17.

TSX:DR

RBC Capital Maintains Sector Perform on Medical Facilities, Raises Price Target to C$17

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a pric...

Evercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Organon (OGN –...

Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL), Organon (OGN) and Haleon PLC Sponsored ADR (HLN)

Shares of companies developing therapies for the liver disease metabolic steatohepatitis, or MASH, are rallying after Novo Nordisk (NVO) said its G...

Madrigal, 89Bio jump after Novo's semaglutide shows promise in MASH

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $400.00...

Jefferies Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Travere Therap...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)

B. Riley analyst Mayank Mamtani raised the firm's price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on t...

Madrigal Pharmaceuticals price target raised to $236 from $194 at B. Riley

Sagimet draws buy at UBS on MASH opportunity

Paulson & Co. exits AngloGold Ashanti, boosts Madrigal Pharma among Q3 moves

AKRO

ATUS

CDXC

EPIX

ETNB

NONOF

REGN

SGMT

TVTX

Earnings

Press Releases

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Arcellx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biohaven

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

B. Riley Securities

Oppenheimer

HC Wainwright & Co.

Citigroup

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 마드리갈 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41648647" target="_blank" rel="noreferrer noopener">예상보다 좋은 실적</a>을 발표한 후 51.70% 상승했다.
2. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41583831" target="_blank" rel="noreferrer noopener">예상보다 좋은 3분기 재무 실적</a>과 2024 회계연도 매출 가이던스를 상향 조정했다고 발표한 후 34.20% 상승했다. 또한, 한 주주가 주당 91달러에 보통주 1억 7,500만 달러를 공모했다.
3. 글로벌스타(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>)의 주식은 회사가 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)과의 서비스 계약을 수정하여 새로운 위성과 인프라로 확장된 MSS 네트워크를 출시한다고 발표한 후 33.98% 상승했다.
4. 진Dx 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식은 회사가 예상보다 좋은 실적을 발표하고 <a href="https://www.benzinga.com//node/41602881" target="_blank" rel="noreferrer noopener">2024 회계연도 매출 가이던스를 상향 조정</a>한 후 31.17% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/wgs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
5. 넥스트래커(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>)의 주식은 회사가 2분기 실적을 발표하고 2025 회계연도 GAAP <a href="https://www.benzinga.com//node/41635816" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 상향 조정</a>한 후 25.91% 상승했다.
6. V.F. 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>)의 주식은 회사가 2분기 재무 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/41599918" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 25.82% 상승했다. 이 회사는 팀버랜드(Timberland)의 모기업이다.
7. 옴니셀(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>)의 주식은 회사가 3분기 실적을 발표하고 2024 회계연도 가이던스를 <a href="https://www.benzinga.com//node/41619987" target="_blank" rel="noreferrer noopener">예상치 이상으로 상향 조정</a>한 후 23.22% 상승했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/omcl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EB%B0%8F-%EC%97%90%EC%8A%A4%ED%8B%B0-%EB%A1%9C%EB%8D%94%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">슈퍼 마이크로 및 에스티 로더는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EB%A1%9C%EB%B8%94%EB%A1%9D%EC%8A%A4-%EB%B0%8F-%EA%B0%80%EB%AF%BC%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Madrigal Pharmaceuticals

뉴스

에 대한 최신 뉴스 Madrigal Pharmaceuticals (NASDAQ:MDGL) 주식

일요일, 11월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌